d9c3eecc10
- Source: inbox/queue/2026-05-09-pmc12374370-glp1-parkinson-updated-meta-analysis-2025.md - Domain: health - Claims: 0, Entities: 1 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
1.8 KiB
| type | entity_type | name | full_name | domain | status |
|---|---|---|---|---|---|
| entity | research_program | MOST-ABLE Trial | Oral Semaglutide for Parkinson's Disease Motor Symptoms Trial | health | active |
MOST-ABLE Trial
Type: Phase 2/3 randomized controlled trial
Intervention: Oral semaglutide 7mg and 14mg daily
Population: n=99 patients with Parkinson's disease
Location: Japan
Primary Endpoint: Motor symptom improvement (MDS-UPDRS Part III)
Overview
MOST-ABLE is the first randomized controlled trial testing semaglutide specifically for Parkinson's disease motor symptoms. Unlike prior GLP-1 Parkinson's trials (exenatide, liraglutide, lixisenatide), this study uses oral semaglutide, which has a distinct CNS access mechanism via tanycytes targeting hypothalamus and brainstem regions.
Significance
The trial addresses a critical evidence gap: all prior GLP-1 Parkinson's RCTs used older GLP-1 agonists with different CNS penetrance profiles. Exenatide's Phase 3 failure (Lancet Feb 2025) revealed that blood-brain barrier crossing does not guarantee substantia nigra penetrance. Semaglutide's tanycyte-mediated CNS access may provide superior regional distribution, but this remains empirically unproven.
Timeline
- 2024 — Protocol published, enrollment completed
- Nov-Dec 2025 — Data collection completed
- 2026 — Results expected (as of May 2026, publication pending)
Context
Meta-analysis of 5 prior GLP-1 Parkinson's RCTs (n=708) shows narrow motor benefit (MDS-UPDRS Part III -2.06, 95% CI -4.09 to -0.03) but no functional quality of life improvement. MOST-ABLE results will determine whether semaglutide's distinct CNS access mechanism translates to superior clinical efficacy.
Sources
- PMC12374370 meta-analysis (Jan 2025)
- Session 40 GLP-1 Parkinson's divergence analysis (May 2026)